Change Of Directors Interest Notice
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/ 0 9/ 01 Amended 01/01/11 Name of entity Regis Healthcare Limited ABN 11 125 203 054 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205 G of the Corporations Act. Name of Director Linda Jane Mellors Date of last notice 13 March 2020 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the respons ible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct ? Nature of direct/ indirect i nterest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Rights granted to Dr Mellors by the Company pursuant to the 2021 Variable Reward and Retention Plan (VRRP) approved at the Annual Genera l Meeting held on 26 October 2021 (subject to a continued employment condition) Date of change 17 November 2021 No. of securities held prior to change 158,000 Ordinary shares Class R ights (unquoted) Appendix 3Y Change of Director’s Interest Notice + Se e chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Number acquired 76,893 R ights (unquoted) which will v est as follows subject to continued employment: 13,072 27 October 2022 25,375 27 October 2023 38,446 28 Octobe r 2024 Upon vesting, each Right may be exercised and converted to one fully paid Ordinary Share in the Company. The Board retains a discreti on to make a cash equivalent payment instead of an allocation of shares. ? Number disposed N/A Value/Consideration Note: If consideration is non - cash, provide details and estimated valuation No cash consideration . Performance Rights issued to the Manag ing Director as part of VRRP . $158,400 cash equivalent value and Rights based on the $2.06 volume weighted average price over 5 trading day period from 16 September 2021 to 22 September 2021 ) No. of securities held after change 158,000 Ordinary shares 76 ,893 R ights (unquoted) Nature of change Example: on - market trade, off - market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy - back Rights granted to Dr Mellors by the Company pursuant to the 2021 Varia ble Reward and Retention Plan (VRRP) approved at the Annual General Meeting held on 26 October 2021 (subject to a continued employment condition) Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come w ithin paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non - cash, provide details and an e stimated valuation Interest after change Part 3 – + Closed period Were the interests in the securities or contracts detailed above traded during a + closed period where prior written clearance was required? No If so, was prior written clearance prov ided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?